Literature DB >> 20179157

A novel sphingosine kinase inhibitor induces autophagy in tumor cells.

Vladimir Beljanski1, Christian Knaak, Charles D Smith.   

Abstract

The sphingolipids ceramide, sphingosine, and sphingosine 1-phosphate (S1P) regulate cell signaling, proliferation, apoptosis, and autophagy. Sphingosine kinase-1 and -2 (SK1 and SK2) phosphorylate sphingosine to form S1P, shifting the balanced activity of these lipids toward cell proliferation. We have previously reported that pharmacological inhibition of SK activity delays tumor growth in vivo. The present studies demonstrate that the SK2-selective inhibitor 3-(4-chlorophenyl)-adamantane-1-carboxylic acid (pyridin-4-ylmethyl)amide (ABC294640) induces nonapoptotic cell death that is preceded by microtubule-associated protein light chain 3 cleavage, morphological changes in lysosomes, formation of autophagosomes, and increases in acidic vesicles in A-498 kidney carcinoma cells. ABC294640 caused similar autophagic responses in PC-3 prostate and MDA-MB-231 breast adenocarcinoma cells. Simultaneous exposure of A-498 cells to ABC294640 and 3-methyladenine, an inhibitor of autophagy, switched the mechanism of toxicity to apoptosis, but decreased the potency of the SK2 inhibitor, indicating that autophagy is a major mechanism for tumor cell killing by this compound. Induction of the unfolded protein response by the proteasome inhibitor N-(benzyloxycarbonyl)leucinylleucinylleucinal Z-Leu-Leu-Leu-al (MG-132) or the heat shock protein 90 inhibitor geldanamycin synergistically increased the cytotoxicity of ABC294640 in vitro. In severe combined immunodeficient mice bearing A-498 xenografts, daily administration of ABC294640 delayed tumor growth and elevated autophagy markers, but did not increase terminal deoxynucleotidyltransferase-mediated dUTP nick end labeling-positive cells in the tumors. These data suggest that ABC294640 promotes tumor cell autophagy, which ultimately results in nonapoptotic cell death and a delay of tumor growth in vivo. Consequently, ABC294640 may effectively complement anticancer drugs that induce tumor cell apoptosis.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20179157      PMCID: PMC2872961          DOI: 10.1124/jpet.109.163337

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  39 in total

1.  Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors.

Authors:  T C Chou; P Talalay
Journal:  Adv Enzyme Regul       Date:  1984

2.  Effect of chemically well-defined sphingosine and its N-methyl derivatives on protein kinase C and src kinase activities.

Authors:  Y Igarashi; S Hakomori; T Toyokuni; B Dean; S Fujita; M Sugimoto; T Ogawa; K el-Ghendy; E Racker
Journal:  Biochemistry       Date:  1989-08-22       Impact factor: 3.162

Review 3.  Regulation of gene expression by SREBP and SCAP.

Authors:  P A Edwards; D Tabor; H R Kast; A Venkateswaran
Journal:  Biochim Biophys Acta       Date:  2000-12-15

4.  New colorimetric cytotoxicity assay for anticancer-drug screening.

Authors:  P Skehan; R Storeng; D Scudiero; A Monks; J McMahon; D Vistica; J T Warren; H Bokesch; S Kenney; M R Boyd
Journal:  J Natl Cancer Inst       Date:  1990-07-04       Impact factor: 13.506

5.  Ceramide-mediated macroautophagy involves inhibition of protein kinase B and up-regulation of beclin 1.

Authors:  Francesca Scarlatti; Chantal Bauvy; Annamaria Ventruti; Giusy Sala; Françoise Cluzeaud; Alain Vandewalle; Riccardo Ghidoni; Patrice Codogno
Journal:  J Biol Chem       Date:  2004-02-17       Impact factor: 5.157

6.  Regulation of an ATG7-beclin 1 program of autophagic cell death by caspase-8.

Authors:  Li Yu; Ajjai Alva; Helen Su; Parmesh Dutt; Eric Freundt; Sarah Welsh; Eric H Baehrecke; Michael J Lenardo
Journal:  Science       Date:  2004-05-06       Impact factor: 47.728

7.  Pharmacology and antitumor activity of ABC294640, a selective inhibitor of sphingosine kinase-2.

Authors:  Kevin J French; Yan Zhuang; Lynn W Maines; Peng Gao; Wenxue Wang; Vladimir Beljanski; John J Upson; Cecelia L Green; Staci N Keller; Charles D Smith
Journal:  J Pharmacol Exp Ther       Date:  2010-01-08       Impact factor: 4.030

8.  Discovery and evaluation of inhibitors of human sphingosine kinase.

Authors:  Kevin J French; Randy S Schrecengost; Brian D Lee; Yan Zhuang; Staci N Smith; Justin L Eberly; Jong K Yun; Charles D Smith
Journal:  Cancer Res       Date:  2003-09-15       Impact factor: 12.701

9.  Down-regulation of sphingosine kinase-1 by DNA damage: dependence on proteases and p53.

Authors:  Tarek A Taha; Walid Osta; Lina Kozhaya; Jacek Bielawski; Korey R Johnson; William E Gillanders; Ghassan S Dbaibo; Yusuf A Hannun; Lina M Obeid
Journal:  J Biol Chem       Date:  2004-02-26       Impact factor: 5.157

10.  The signal modulator protein 14-3-3 is a target of sphingosine- or N,N-dimethylsphingosine-dependent kinase in 3T3(A31) cells.

Authors:  T Megidish; T White; K Takio; K Titani; Y Igarashi; S Hakomori
Journal:  Biochem Biophys Res Commun       Date:  1995-11-22       Impact factor: 3.575

View more
  57 in total

Review 1.  Sphingosine-1-phosphate antibodies as potential agents in the treatment of cancer and age-related macular degeneration.

Authors:  Roger A Sabbadini
Journal:  Br J Pharmacol       Date:  2011-03       Impact factor: 8.739

Review 2.  Sphingosine-1-phosphate and immune regulation: trafficking and beyond.

Authors:  Hongbo Chi
Journal:  Trends Pharmacol Sci       Date:  2010-12-14       Impact factor: 14.819

3.  Downregulation of Critical Oncogenes by the Selective SK2 Inhibitor ABC294640 Hinders Prostate Cancer Progression.

Authors:  Randy S Schrecengost; Staci N Keller; Matthew J Schiewer; Karen E Knudsen; Charles D Smith
Journal:  Mol Cancer Res       Date:  2015-08-13       Impact factor: 5.852

Review 4.  Evolving concepts in cancer therapy through targeting sphingolipid metabolism.

Authors:  Jean-Philip Truman; Mónica García-Barros; Lina M Obeid; Yusuf A Hannun
Journal:  Biochim Biophys Acta       Date:  2013-12-30

5.  Combined anticancer effects of sphingosine kinase inhibitors and sorafenib.

Authors:  Vladimir Beljanski; Christian Knaak; Yan Zhuang; Charles D Smith
Journal:  Invest New Drugs       Date:  2010-05-18       Impact factor: 3.850

6.  A Phase I Study of ABC294640, a First-in-Class Sphingosine Kinase-2 Inhibitor, in Patients with Advanced Solid Tumors.

Authors:  Carolyn D Britten; Elizabeth Garrett-Mayer; Steven H Chin; Keisuke Shirai; Besim Ogretmen; Tricia A Bentz; Alan Brisendine; Kate Anderton; Susan L Cusack; Lynn W Maines; Yan Zhuang; Charles D Smith; Melanie B Thomas
Journal:  Clin Cancer Res       Date:  2017-04-18       Impact factor: 12.531

7.  Autophagosomal membrane serves as platform for intracellular death-inducing signaling complex (iDISC)-mediated caspase-8 activation and apoptosis.

Authors:  Megan M Young; Yoshinori Takahashi; Osman Khan; Sungman Park; Tsukasa Hori; Jong Yun; Arun K Sharma; Shantu Amin; Chang-Deng Hu; Jianke Zhang; Mark Kester; Hong-Gang Wang
Journal:  J Biol Chem       Date:  2012-02-23       Impact factor: 5.157

8.  Inhibition of sphingosine kinase 2 downregulates the expression of c-Myc and Mcl-1 and induces apoptosis in multiple myeloma.

Authors:  Jagadish Kummetha Venkata; Ningfei An; Robert Stuart; Luciano J Costa; Houjian Cai; Woodrow Coker; Jin H Song; Kiwana Gibbs; Terri Matson; Elizabeth Garrett-Mayer; Zhuang Wan; Besim Ogretmen; Charles Smith; Yubin Kang
Journal:  Blood       Date:  2014-09-18       Impact factor: 22.113

Review 9.  Therapeutic potential of targeting sphingosine kinases and sphingosine 1-phosphate in hematological malignancies.

Authors:  C Evangelisti; C Evangelisti; F Buontempo; A Lonetti; E Orsini; F Chiarini; J T Barata; S Pyne; N J Pyne; A M Martelli
Journal:  Leukemia       Date:  2016-07-27       Impact factor: 11.528

Review 10.  Sphingolipids: regulators of crosstalk between apoptosis and autophagy.

Authors:  Megan M Young; Mark Kester; Hong-Gang Wang
Journal:  J Lipid Res       Date:  2012-11-13       Impact factor: 5.922

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.